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Abstract
Introduction: Autoreactive T cells are a central element in many systemic autoimmune diseases. The generation of
these pathogenic T cells is instructed by antigen-presenting cells (APCs). However, signaling pathways in APCs that
drive autoimmune diseases, such as rheumatoid arthritis, are not understood.
Methods: We measured phenotypic maturation, cytokine production and induction of T cell proliferation of APCs
derived from wt mice and mice with a myeloid-specific deletion of PTEN (myeloid PTEN-/-) in vitro and in vivo. We
induced collagen-induced arthritis (CIA) and K/BxN serum transfer arthritis in wt and myeloid-specific PTEN-/- mice.
We measured the cellular composition of lymph nodes by flow cytometry and cytokines in serum and after ex vivo
stimulation of T cells.
Results: We show that myeloid-specific PTEN-/- mice are almost protected from CIA. Myeloid-specific deletion of
PTEN leads to a significant reduction of cytokine expression pivotal for the induction of systemic autoimmunity
such as interleukin (IL)-23 and IL-6, leading to a significant reduction of a Th17 type of immune response characterized
by reduced production of IL-17 and IL-22. In contrast, myeloid-specific PTEN deficiency did not affect K/BxN serum
transfer arthritis, which is independent of the adaptive immune system and solely depends on innate effector functions.
Conclusions: These data demonstrate that the presence of PTEN in myeloid cells is required for the development of
CIA. Deletion of PTEN in myeloid cells inhibits the development of autoimmune arthritis by preventing the generation of
a pathogenic Th17 type of immune response.
Introduction
Inflammatory joint diseases, such as rheumatoid arthritis
(RA) or psoriatic arthritis (PsA), are chronic disorders
that affect more than 1 % of the population and lead to
significant disability [1, 2]. The hallmark of RA is local
bone destruction mediated by cells of the innate im-
mune system, termed osteoclasts. However, genetic asso-
ciations with major histocompatibility complex (MHC)
II molecules, the presence of autoantibodies such as
rheumatoid factor or anti-citrullinated peptide anti-
bodies, as well as high amounts of T cells in the inflamed
synovial membrane suggest an important involvement of
the adaptive immune system [3–6]. Cumulative evidence
indicates that CD4+ T cells, especially those polarized to-
ward the T helper (Th) 1/Th17 subsets, play a critical
role in the pathogenesis of both RA and PsA [7–9]. Not
only the signature cytokine interleukin (IL)-17 produced
by these Th17 cells, but also IL-21 and IL-22, have been
demonstrated to be present in RA synovial membrane
and fluid [10, 11]. Furthermore Th17 cells were shown
to be involved in various key processes in arthritis devel-
opment such as pannus formation by activation of syn-
ovial fibroblasts and joint destruction by induction of
bone-resorbing osteoclasts [10–12]. As a consequence,
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there is a strong interest in defining the conditions and
factors as well as signaling pathways determining devel-
opment and activity of these pathogenic Th17 cells.
Among various factors involved in the activation of
Th17 cells, antigen-presenting cells (APCs) are thought
to be essential. APCs orchestrate the generation of adap-
tive immune responses by controlling the activation of
antigen-specific T cells [13], as costimulatory molecules
such as CD80 and CD86 provided by APCs are required
to enable activation of naïve T cells via MHC-peptide
complexes [14, 15]. In addition, APCs determine T cell
polarization by the cytokine pattern they release [16, 17].
For example, IL-23, IL-6, and IL-1ß, have been shown to
be indispensable for T cell polarization toward the patho-
genic Th17 subset and are therefore also important for the
development of various autoimmune conditions [12, 18, 19].
However, signal transduction pathways in APCs that govern
the subsequent development of Th17 cells in vivo have not
been identified yet.
The phosphatidylinositol 3-kinase (PI3K) pathway is
one of the most important signal transduction pathways,
regulating not only fundamental processes such as cell
survival, cell migration, proliferation and cytoskeleton re-
modeling [20–22] but also leukocyte activation and im-
mune cell homeostasis [23, 24].
Moreover, PI3K-γ but also PI3K-δ, PI3K family members
enriched in leukocytes are involved in the pathogenesis of
arthritis. Blocking of PI3K-γ or PI3K-δ with antibodies or
their genetic deletion has been shown to diminish inflam-
matory arthritis, due to reduction of leukocyte migration
into the inflamed joints [25–27]. However, to date, there
are no data available about the contribution of the PI3K
pathway in APCs in the induction of autoimmunity.
Phosphatase and tensin homolog (PTEN) is a phos-
phatase antagonizing all classes of PI3K [20, 28]. Using a
genetic approach, where PTEN is deleted only in myeloid
cells (myeloid pten-/-), allowed us therefore to investigate
the role of the PI3K pathway in autoimmunity, specifically
in APCs.
Methods
Antibodies and reagents
Antibodies for western blotting, immunohistochemistry
and fluorescence-activated cell sorting (FACS) analysis
were obtained from: CD11b (Serotec, Raleigh, NC, USA),
CD11c, Gr1, CD25, CD40, CD80, CD86, I-A/I-E: all BD
Biosciences (San Jose, CA, USA), CD4: Beckman Coulter,
(Brea, CA, USA), FoxP3: eBioscience (San Diego, CA, USA).
Lipopolysaccharide (LPS) and CpG DNA were obtained
from Invivogen (San Diego, CA, USA). Wortmannin was
from Sigma-Aldrich (St Louis, MO, USA). Anti-collagen
enzyme-linked immunosorbent assay (ELISA), Mouse
Th1/Th2 10plex FlowCytomix Multiplex as well as IL-23
and IL-22 FlowCytomix simplex were from Bender
MedSystems (Vienna, Austria) and used according to the
manufacturer’s protocols. Antibodies against phospho-AKT,
AKT, were from Cell Signaling (Danvers, MA, USA). ELISA
antibodies against murine IL-6, IL-12/23, interferon (IFN)-γ,
IL-17A, IL-22, IL-4 were obtained from eBioscience.
Mice
Ptenflox/flox mice were provided by Dr. Tak W. Mak. These
mice were crossed with mice expressing the Cre recom-
binase under the control of the lysozyme M (LysM) pro-
moter [29] to generate LysMCreptenflox/flox (myeloid pten-/-)
mice. All mice were on a C57BL/6 J background. For
arthritis experiments, littermates of LysMCreptenflox/flox
(either Cre + (myeloid pten-/-) or Cre – (wild-type (wt))
were used.
All animal studies were approved by the animal ethics
committee of the Medical University Vienna and comply
with institutional guidelines (BMWF-66.009/0103-C/GT/
2007 and BMWF-66.009/0241-II/3b/2011).
Bone marrow-derived dendritic cells
Bone marrow-derived dendritic cells (BMDCs) were gen-
erated as previously described [30]. BMDCs from wt mice
were cultured in the presence of 10 ng/ml granulocyte
macrophage colony-stimulating factor (GM-CSF), with
supplementation on days 0, 3, and 6. On day 7, they
were analyzed by FACS. The BMDC purity was 65–75 %
CD11c+ and Gr1−. They were stimulated with 100 ng/ml
LPS or 10 μg/ml CpG.
Western blotting
BMDC derived from wt or myeloid pten-/- mice were
stimulated with LPS or CpG or medium alone ranging
from 5 to 120 minutes. After stimulation, dendritic cells
(DCs) were lysed in Laemmli buffer, and proteins were
separated by electrophoresis on 10 % SDS-polyacrylamide
gels. Proteins were blotted onto polyvinylidene difluoride
membrane and, after blocking with 5 % dry milk/0.1 %
Tween 20, incubated with primary antibodies in the
same solution. Bound antibodies were detected by anti-
immunoglobulin G (IgG) conjugated with peroxidase and
underwent subsequent chemiluminescent detection.
T cell stimulation in vivo
Carboxyfluorescein succinimidyl ester (CFSE) (Molecular
Probes, Eugene, OR, USA) -labeled OTII cells (3–4 × 106/
mouse) were transferred intravenously (i.v.). After 24
hours, mice were immunized i.v. with 300 μg/mouse
OVA protein (Sigma-Aldrich) together with 75 μg/mouse
LPS (Sigma-Aldrich), or 75 μg LPS alone. After 4 days,
spleen cells were isolated and CFSE dilution of CD4+ and
Vα2+ cells was measured by flow cytometry.
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Quantitative real-time polymerase chain reaction
Total RNA was isolated from cultivated BMDCs or oste-
oclasts using the RNeasy Mini kit (Qiagen, Venlo, The
Netherlands). One micron of total RNA was used for
first-strand cDNA synthesis (Amersham Biosciences,
Little Chalfont, UK) and 1 μl cDNA will then be used for
PCR with specific primers. Primers used were: IL-12p40
fwd: 5′-GAC ACG CCT GAA GAA GAT GAC-3′; IL-
12p40 rev.: 5′-TAG TCC CTT TGG TCC AGT GTG-3′;
IL-23p19 fwd: 5′-ATG CTG GAT TGC AGA GCA
GTA-3′; IL-23p19 rev: 5′-ACG GGG CAC ATT ATT
TTT AGT CT-3′; IL-12p35 fwd: 5′-CCC TTG CCC TCC
TAA ACC AC-3 ′, IL-12p35 rev: 5′-AAG GAA CCC
TTA GAG TGC TTA CT-3 ′, IL-17A fwd: 5′-TCT CAT
CCA GCA AGA GAT CC-3′, IL-17A rev: 5′-AGT TTG
GGA CCC CTT TAC AC-3′, IL-4 fwd: 5′-ACG GCA
CAG AGC TAT TGA TGG-3′, IL-4 rev: 5′-CGA TGA
ATC CAG GCA TCG AA-3′, IFN-γ fwd: 5′-GAT GCA
TTC ATG AGT ATT GCC AAG T-3′, IFN-γ rev:
5′-GTG GAC CAC TCG GAT GAG CT, PTEN fwd:
5′-ACA CCG CCA AAT TTA ACT GC-3′, PTEN
rev: 5′-TAC ACC AGT CCG TCC CTT TC-3′.
Collagen-induced arthritis
Mice were immunized subcutaneously (s.c.) with 50 μg
chicken collagen type II (CII) (Sigma-Aldrich) in 50 μl H2O
emulsified in 50 μl complete Freund’s adjuvant (CFA) that
was enriched with 10 μg/ml Mycobacterium tuberculosis
(H37Ra; Difco/BD Biosciences) and scoring was performed
as described [31]. Briefly, mice were evaluated weekly for
symptoms of arthritis using a semiquantitative scoring
system, which includes degree of joint swelling and grip
strength. Briefly, joint swelling was examined using a
clinical score graded from 0 to 3 (0, no swelling; 1, mild
swelling of toes and ankle; 2, moderate swelling of toes
and ankle 3, severe swelling of toes and ankle). In addition,
grip strength of each paw was analyzed by semiquantita-
tively evaluating the force needed to detach the paw from
a wire 3 mm in diameter using a score from 0 to –3 (0,
normal grip strength; –1 mildly reduced grip strength; –2
moderately reduced grip strength; –3, severely reduced
grip strength). Assessments were performed in a blinded
fashion. Scoring was performed by the same assessor for
the whole experiment.
Evaluation of inflammation, local bone erosions and
cartilage destruction by histological examination
Stainings were performed as previously described [32].
For exact quantification of the areas of inflammation,
hematoxylin and eosin (H&E) sections were evaluated
using Osteomeasure software (OsteoMetrics, Atlanta, GA,
USA).
Serum transfer arthritis
After intraperitoneal (i.p.) application of 150 μl of K/BxN
serum at day 1 and day 3, mice were scored clinically
every other day with a semiquantitative scoring system as
for collagen-induced arthritis (CIA) (see above) and sacri-
ficed at day 12 and tissue was prepared for histology.
Flow cytometric analysis of the draining lymph nodes
Draining lymph nodes (LNs) were harvested and passed
through a nylon mesh to obtain single-cell suspensions.
Cells were then stained with the indicated antibodies and
analyzed by flow cytometry (BD FACScanto II, FACSdiva
software) (BD Biosciences).
Results
PTEN regulates T cell-polarizing cytokines in APCs
We first stimulated bone marrow cells from wt and
myeloid pten-/- animals with GM-CSF to generate bone
marrow-derived DCs (BMDCs). We confirmed by quan-
titative real-time polymerase chain reaction (qPCR) that
BMDCs from myeloid pten-/- were indeed deficient in
PTEN (Additional file 1). We then stimulated these cells
with LPS, a ligand for Toll-like receptor (TLR) 4, and CpG
DNA, a ligand for TLR9, to induce phenotypic maturation
in vitro. We found no differences regarding the upregula-
tion of costimulatory molecules such as CD80, CD86 or
CD40 between pten -/- and wt BMDCs (Fig. 1a).
To investigate maturation of primary DCs in vivo, we
analyzed splenic DCs of wt and myeloid pten-/- animals
after i.p. challenge with LPS. In line with the data obtained
in vitro, we did not detect differences in the upregulation
of CD86 or MHC II on CD11c+ cells (Fig. 1b).
In order to test the ability of APCs from wt or myeloid
pten-/- animals to induce proliferation of T cells, we
transferred CFSE-labeled OTII cells into wt and myeloid
pten-/- animals and measured proliferation in the OTII
cell transplant after immunization with ovalbumin plus
LPS by CFSE dilution ex vivo. We did not detect differ-
ences in the proliferation of OTII cells transferred into wt
or myeloid pten-/- animals after immunization (Fig. 1c).
Taken together, these data show that neither APC mat-
uration nor primary T cell activation was altered in mye-
loid pten-/- animals when compared to wt animals.
We next analyzed the production of IL-6 and IL-12p40
in BMDCs after LPS challenge. Induction of both cyto-
kines was significantly lower in myeloid pten -/- BMDCs
compared to littermate-derived wt cells. Looking at RNA
levels, we also found reduced upregulation of the IL-23
and IL-12 subunits IL-23p19, IL-12p40 and IL-12p35,
IL-6 as well as IFN-β in myeloid pten -/- BMDCs com-
pared to wt cells (Fig. 1d and Additional file 1 B, C). The
reduced expression of IL-12p40 and IL-23p19 in BMDCs
derived from myeloid pten-/- mice could be reversed by
the addition of the PI3K inhibitor wortmannin, indicating
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a PI3K-dependent effect (Additional file 2A). Western blot
analysis confirmed increased phosphorylation of AKT
under basal and LPS-stimulated conditions (Additional
file 2B). Taken together, these data reveal that PTEN
deficiency in BMDCs leads to constitutive activation of
the PI3K pathway with reduced production of polarizing
cytokines albeit an intact capacity to activate naïve T
cells.
PTEN deficiency in APCs prevents collagen-induced
arthritis
We next investigated the influence of myeloid PTEN de-
ficiency in CIA, a well-established animal model of human
RA. We found that myeloid pten-/- animals developed
hardly any clinical symptoms of arthritis (Fig. 2a). In
addition, the incidence of arthritis was significantly lower
in myeloid pten-/- animals (Fig. 2b). In line with this, we
Fig. 1 PTEN does not influence DC maturation but importantly regulates T cell polarizing cytokines in vitro. a BMDCs were either unstimulated or
stimulated with the TLR ligands LPS (100 ng/ml) or CpG (5 μg/ml) and analyzed by flow cytometry. Plots show indicated surface markers on gated CD11c+
cells. Data are representative of at least three experiments. b Upregulation of CD86 and MHCII on CD11c+ cells in wt (n = 5) and myeloid pten -/- (n = 5)
after administration of LPS (75 μg) i.p. measured by flow cytometry. c Analysis of CFSE dilution of transferred OTII cells 3 days after transfer into wt or
myeloid pten -/- mice and immunization with LPS and ovalbumin i.v. d Analysis of levels of IL-6 and IL-12p40 in the supernatants of wt or myeloid pten-/-
BMDCs stimulated with LPS. BMDC bone marrow-derived dendritic cell, CFSE carboxyfluorescein succinimidyl ester, DC dendritic cell, IL interleukin,
i.p. intraperitoneally, i.v. intravenously, LPS lipopolysaccharide, MHC major histocompatibility complex, PTEN phosphatase and tensin homolog,
TLR Toll-like receptor, wt wild-type
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detected almost no synovial inflammation or local bone
destruction (erosions) in histological sections of myeloid
pten-/- compared to wt animals (Fig. 2c). In addition, we
found significantly reduced numbers of osteoclasts as
well as the amount of cartilage damage in the joints of
myeloid pten-/- animals compared to wt animals (Fig. 2c
and d). Interestingly, we detected no difference in the
anti-collagen IgG titers, excluding the possibility that
reduced production of anti-collagen antibodies prevented
the development of arthritis in myeloid pten-/- animals
(Fig. 2e).
In order to understand the mechanism of the protective
effect of myeloid pten-/- animals in CIA, we first analyzed
serum levels of proinflammatory cytokines 4 weeks after
Fig. 2 Myeloid pten-/- animals are protected from collagen-induced arthritis (CIA). a Clinical quantification of paw swelling in wt (n = 7) and
myeloid pten-/- (n = 13) mice after induction of CIA. Data are expressed as means ± s.e. *P ≤ 0.05, **P ≤ 0.01. b Incidence plot of arthritis of wt
and myeloid pten-/- after induction of CIA (*P ≤ 0.05). Plot shows data from one representative experiment of two with similar results. c Quantitative
histomorphometric analysis of hind paws of wt and myeloid pten-/- mice after induction of CIA. Data are expressed as means ± s.d. *P ≤ 0.05,
**P ≤ 0.01. d Representative images and TRAP-stained histologies of hind paws of wt and myeloid pten-/- mice. Scale bars, 0.5 mm. e Quantification
of anti-collagen IgG antibody levels of wt (n = 7) and myeloid pten-/- (n = 13) mice after induction of CIA. Data are means ± s.d. IgG immunoglobulin G,
TRAP tartrate-resistant acid phosphatase, wt wild-type
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induction of CIA. We measured profoundly reduced
amounts of the Th17-related cytokines IL-17 and IL-23 as
well as IL-6 in myeloid pten-/- mice compared to wt litter-
mates. Serum levels of interferon-γ and IL-4, however,
were not different between the two groups (Fig. 3).
We next evaluated, whether PTEN deficiency in mye-
loid cells influences the induction of an antigen-specific
cellular immune response to collagen. As migration of
antigen-loaded APCs to the draining LN is a prerequisite
for this response in vivo, we first analyzed the cellular
composition of draining LNs in wt and myeloid pten-/-
animals after induction of CIA. We found no difference
between myeloid pten-/- and wt animals in the relative
abundance of APCs, such as CD11c+ DCs or CD11b+
macrophages (Fig. 4a and b). We next analyzed the mat-
uration state of APCs in the draining LN in vivo and
found, in line with our in vitro data, no significant differ-
ences in the surface expression of CD80, CD86 or MHC
II on CD11c+ or CD11b+ cells (Fig. 4a and b).
Of note, the relative numbers of CD4+ T cells as well
as activated (CD4+CD25+) T cells did not differ between
the groups (Fig. 4c). Moreover, in vitro restimulation of
spleen cells with collagen 14 days after induction of CIA
resulted in similar proliferation of T cells in wt and
myeloid pten-/- mice (Fig. 4d), suggesting that antigen-
specific T cell activation after induction of CIA is not
altered by the absence of PTEN in myeloid cells.
These data demonstrate that the marked reduction of
joint inflammation in myeloid pten-/- mice is not caused
by alterations of the migratory pattern, the maturation
state of APCs or the subsequent T cell activation after
immunization with collagen.
PTEN in APCs allows for priming of Th17 cells in vivo
As the development of CIA critically depends on the
generation of Th17 cells [12, 33] and we have found re-
duced levels of Th17-related cytokines in the serum of
myeloid pten-/- mice, we next analyzed the impact of
PTEN deficiency in myeloid cells on T cell polarization
in CIA. Therefore, we harvested the draining LNs of wt
and myeloid pten-/- mice 14 days after immunization with
collagen and determined mRNA expression of cytokines
specific for polarized T cells by qPCR. We found a reduc-
tion of the mRNA transcripts specific for Th17 cytokines,
i.e., IL-17 and IL-22, and concomitantly an increase of the
Th2 cytokine IL-4, whereas mRNA levels of the Th1 cyto-
kine IFN-γ were not altered between the groups (Fig. 5a).
Analysis of supernatants from draining LN cells after
in vitro stimulation with anti-CD3 revealed a similar
pattern. We detected a significant reduction of the Th17
cytokines IL-17 as well as IL-22. There was a trend toward
higher IL-4 levels, while IFN-γ expression was unchanged
(Fig. 5b). The proliferative response after anti-CD3
Fig. 3 Diminished induction of Th17-related cytokines in myeloid pten -/- mice after induction of collagen-induced arthritis (CIA). Serum samples
of wt (n = 16) and myeloid pten-/- (n = 9) mice obtained 4 weeks after induction of CIA. Levels of the indicated cytokines were analyzed by ELISA.
Horizontal bars are means of each group ± s.e. Each data point represents an individual animal *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. ELISA enzyme-linked
immunosorbent assay, Th T helper, wt wild-type
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stimulation was equivalent in LN cells of both groups
(Additional file 3).
These data demonstrate reduced priming of Th17 cells
in myeloid pten-/- mice, with concomitant slight increase
in the production of Th2 cytokines. Hence, myeloid pten-/-
mice are protected from CIA due to reduced Th17 prim-
ing capabilities of PTEN-/- APCs. These data also confirm
the essential role of the PI3K/PTEN pathway in myeloid
cells in the generation of Th17-mediated autoimmune
disease.
Absence of PTEN in APCs does not affect the development
of arthritis that is solely dependent on innate effector
mechanisms
In myeloid pten-/- mice not only APCs but also neutrophil
granulocytes and macrophages are lacking PTEN.
Consequently we tested whether the absence of PTEN
in granulocytes and macrophages might reduce their
potential to migrate into the synovial membrane or their
destructive capabilities using the K/BXN serum transfer
arthritis model [34, 35]. This model depends only on in-
nate effector mechanisms, as a cocktail of arthritogenic
antibodies transferred into wt recipients is sufficient to in-
duce an inflammatory erosive arthritis even in the absence
of a functioning adaptive immune system [35, 36].
We found, that time of onset and clinical severity of
serum transfer arthritis was not altered in myeloid pten-/-
mice as compared to their wt littermates (Fig. 6a and b).
In line, when we evaluated the histological signs of arth-
ritis we found no difference in the degree of synovial in-
flammation or local bone erosions in both groups (Fig. 6c
and d). These results show that effector mechanisms
Fig. 4 PTEN is not critically involved in APC migration and phenotypic maturation in vivo. a–c Cells of draining LN from wt (n = 4) and myeloid pten -/-
mice (n = 6) 2 weeks after induction of CIA and analyzed by flow cytometry. CD11c+ DCs (a) and CD11b+ macrophages (b) (shown as percent of total
LN cells), and expression levels of CD80, CD86 and MHC II (mean fluorescence intensity, mfi) on CD11c+ cells or CD11b+ cells. c CD4+ T cells and CD4+
CD25+ activated T cells (shown as percent of total CD4+ cells). Horizontal bars are means of each group ± s.e. d Spleen cells from wt or myeloid pten -/-
mice of mock immunized (adjuvants only, left two bars) or after immunization with collagen (right two bars) were restimulated with 100 μg/ml collagen II
in vitro and proliferation was quantified by H3Thymidine incorporation. Data are expressed as means ± s.d. APC antigen-presenting cell, CIA
collagen-induced arthritis, DCs dendritic cells, LN lymph node, MHC major histocompatibility complex, PTEN phosphatase and tensin homolog
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Fig. 5 PTEN in APCs allows for priming of Th17 cells in vivo. a, b Cells of draining LN of wt (n = 4) and myeloid pten -/- (n = 6) mice were harvested 2
weeks after induction of CIA. a mRNA levels of the indicated cytokines were determined by qPCR. Horizontal bars are means of each group ± s.e. Each
data point represents an individual animal *P ≤ 0.05. b LN cells of wt and myeloid pten -/- mice were stimulated in vitro with anti-CD3 for 3 days and
levels of the indicated cytokines in the supernatant were measured by ELISA. Horizontal bars are means of each group ± s.d. Each data point represents
an individual animal *P ≤ 0.05. APCs antigen-presenting cells, CIA collagen-induced arthritis, ELISA enzyme-linked immunosorbent assay, LN lymph
node, PTEN phosphatase and tensin homolog, qPCR quantitative real-time polymerase chain reaction, Th T helper, wt wild-type
Fig. 6 Absence of PTEN in APCs does not affect the development of innate immunity-dependent arthritis. a, b Clinical assessment of (a) paw
swelling and (b) grip strength in wt (n = 7) and myeloid pten -/- (n = 7) after induction of K/BxN serum transfer arthritis. Data are expressed as
means ± s.d. C Quantitative histomorphometric analysis of the hind paws of wt and myeloid pten -/- mice 12 days after induction of K/BxN serum
transfer arthritis. Data are expressed as means ± s.d. *P ≤ 0.05. d Representative histologies of hind paws of wt and myeloid pten -/- mice obtained
12 days after induction of K/BxN serum transfer arthritis (H&E staining, TRAP staining). Scale bars, 1 mm. APCs antigen-presenting cells, H&E hematoxylin
and eosin, PTEN phosphatase and tensin homolog, TRAP tartrate-resistant acid phosphatase, wt wild-type
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leading to inflammatory arthritis remain intact in myeloid
pten-/- animals in K/BXN serum transfer arthritis, which is
independent of antigen presentation by APCs and the in-
duction of an adaptive immune response.
Discussion
Here we describe a novel function of the PI3K pathway
in controlling autoimmune arthritis. We used conditional
knockout animal models where PTEN deficiency is
achieved selectively in the entire myeloid cell compart-
ment [29, 37] with all other cell types being sufficient
for PTEN. With this strategy we were able to investi-
gate the role of PTEN in the induction of autoimmunity
without any interference of potential effects of the
PI3K/PTEN axis on T and B cells or the mesenchymal
cell compartment. We demonstrate that PTEN deficiency
in APCs almost completely prevents CIA by reducing the
generation of pathogenic T helper cells. The PI3K pathway
has been implicated in APCs in the regulation of T helper
cell differentiation: deletion of the p85 regulatory subunit
of PI3K resulted in an increased production of IL-12
in vitro, leading to enhanced Th1-mediated immunity in a
Leishmania infection model [38]. In line with these data,
PTEN-/- APCs exhibit a reduced capacity to produce cyto-
kines such as IL-23 and IL-6, which importantly shape
subsequent Th responses [7, 17]. In our murine model for
RA, this translates into a severely reduced generation of
pathogenic IL-17- and IL-22-producing cells.
In CIA, significantly reduced levels of IL-17 were
present in the serum and also in draining LNs after in-
duction of CIA. However, the proliferative response of T
cells stimulated by wt or PTEN-deficient DCs was com-
parable in vitro as well as in vivo in various analyses,
demonstrating clearly that the quality but not the quan-
tity of the T cell response was altered in the absence of
PTEN in DCs. Of note, the humoral response upon
immunization with collagen was comparable in wt and
myeloid pten-/- mice. This shows again that it is not the
general activation of the adaptive immune system that is
impaired in myeloid pten-/- mice, but the quality of the
response. In addition, we found no difference in the ex-
tent of serum transfer arthritis and we recently reported
that tumor necrosis factor (TNF)-driven arthritis is even
augmented in myeloid pten-/- compared to wt animals,
especially with respect to bone destruction, due to in-
creased osteoclastogenic potential of PTEN-deficient mye-
loid cells [39]. Therefore, the major phenotype we detect
in myeloid pten-/- mice reflects an inability to mount an
adaptive immune response that is able to induce joint
pathology in these mice. Reduced production of T cell-
polarizing cytokines such as IL-6 and IL-23 by myeloid
pten-/- APCs in vitro as well as in vivo after induction of
CIA leads to reduced generation of IL-17- and IL-22-
producing T cells, which in turn are required to induce
arthritis in CIA animals. In contrast, in serum transfer
arthritis, where the pathogenesis of joint pathology solely
depends on innate effector mechanisms, we did not detect
differences in clinical as well as histological signs of arth-
ritis. Thus, in two arthritis models, which are independent
of adaptive immunity, intact effector mechanisms in mye-
loid pten-/- mice have been observed, highlighting the pro-
found effect of PTEN in APC for the induction phase of
immune-mediated arthritis.
Interestingly, activation of the PI3K pathway in CD4+
T cells is necessary for Th17 polarization, as demonstrated
by significantly reduced generation of IL-17-producing T
cells in p85α-deficient CD4 cells [40]. This suggests op-
posite requirements and functions of PI3-kinase signaling
in APCs and T cells in Th17 polarization in vivo.
While the data presented here suggest a pivotal role of
PTEN expression in APCs in the generation of auto-
immune arthritis, it is conceivable that PTEN could con-
trol arthritis also via activity in other cell types. In this
respect, reports demonstrating a protective role of PI3K-γ
deficiency in CIA, mainly due to effects on migration of ef-
fector cells into the inflamed joints should be mentioned
[25]. In addition, loss of PTEN expression in fibroblasts
was noted at areas of joint damage in RA patients [41]. Fur-
thermore, CIA was ameliorated by delivering an adenoviral
construct silencing PTEN directly to the inflamed joint,
suggesting events downstream of antigen presentation [42].
These observations suggest that the PI3K/PTEN axis con-
trols multiple aspects in the pathogenesis of inflammatory
diseases in different tissues such as cell migration, invasive
behavior, cytokine production and proliferation, and T cell
polarization. There are known examples of different effects
of one and the same signal transduction pathway depend-
ing on the cell type analyzed. Rapamycin, a widely used im-
munosuppressive agent, has potent and well-described
inhibitory effects on Tcells by blocking the mechanistic tar-
get of rapamycin (mTOR) in these cells [43]. Rapamycin,
on the other hand has also immunostimulatory effects on
myeloid cells, which are thought to be responsible for some
of its serious clinical side effects such as fever, pneumonitis
or glomerulonephritis [44]. It is therefore of tremendous
importance to dissect the biological effects of signal trans-
duction pathways in a tissue-specific manner, especially in
the light of possible therapeutic interventions in humans.
APCs are pivotal to generate the desired immunity against
microbial infections but can also initiate self-destructing
autoimmunity. It is therefore imperative to decipher the
molecular mechanisms controlling the immunomodulatory
potential of APCs in order to enable their modification for
therapeutic interventions.
Conclusions
Our data provide the first evidence for the pivotal and
previously unanticipated role of the PI3K/PTEN pathway
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in APCs in controlling autoimmune arthritis. Sustained
PI3K signaling in myeloid cells protects from pathology
via inhibition of the polarization of self-reactive Th17
cells (Additional file 4). These findings may pave the way
for selective novel targeted therapies for chronic destruc-
tive arthritis and possibly other inflammatory disorders.
Additional files
Additional file 1: (A) BMDCs from wt or myeloid pten -/- animals were
analyzed for pten mRNA expression by qPCR. (B) Quantitative PCR
analysis of wt or myeloid pten-/- BMDCs stimulated with CpG (5 μg/ml) for
the indicated mRNAs. Data are expressed as mean values ± s.d. *P ≤ 0.05.
(JPEG 336 kb)
Additional file 2: (A) BMDCs from wt or DC pten -/- animals were
analyzed for the expression of the indicated mRNAs by qPCR. (B)
BMDCs from wt or DC pten -/- animals were stimulated as indicated and
analyzed by western blot for the indicated proteins. (JPEG 214 kb)
Additional file 3: Cells of the draining LN of wt (n = 4) and myeloid
pten -/- (n = 6) mice 2 weeks after induction of CIA were stimulated
with plate-bound anti-CD3 for 3 days. H3 Thymidine incorporation
was used to quantify proliferation. Data are expressed as means ± s.d.
(JPEG 134 kb)
Additional file 4: Schematic representation of APC activation in wt
and myeloid pten -/- animals. In wt, APCs are activated and initiate
autoimmunity by activating and polarizing T cells toward the Th17 lineage.
PTEN-deficient APCs fail to induce autoimmunity due to sustained PI3K
signaling, leading to altered signaling and reduced polarizing cytokine
expression. (JPEG 294 kb)
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